1-5 of 5
Ying Zhu, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data

Lijun Yao, MS, Reyka G Jayasinghe, PhD, Tianjiao Wang, BA, Julie O'Neal, PhD, Ruiyang Liu, BS, Michael P. Rettig, PhD, Chia-Feng Tsai, PhD, Steven M. Foltz, BS, MS, Danny Kohnen, MBA, Smrithi Mani, BS, Fernanda Martins Rodrigues, MSc, Michael C. Wendl, D SC, MS, PHS, Matthew A. Wyczalkowski, PhD, Scott R. Goldsmith, MD, Ying Zhu, PhD, Mark A Fiala, MSW, Liu Tao, BS, PhD, Ravi Vij, MD MBA, Li Ding, PhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-142205
Published: 2020
Journal Articles

Single-Cell Transcriptomic and Proteomic Diversity in Multiple Myeloma

Reyka G Jayasinghe, PhD, Yige Wu, BS, Ying Zhu, PhD, Ruiyang Liu, BS, Mark A. Fiala, BS, Daniel R. Kohnen, MBA, Chia-Feng Tsai, PhD, Smrithi Mani, BS, Justin King, BS, Michael P. Rettig, PhD, Julie O'Neal, PhD, Tianjiao Wang, BA, Steven M. Foltz, BS, MS, Lijun Yao, MS, Hua Sun, PhD, Catrina Fronick, BS, Scott R. Goldsmith, MD, John F. DiPersio, MD PhD, Ravi Vij, MBBS, Liu Tao, BS, PhD, Li Ding, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5531.
https://doi.org/10.1182/blood-2019-131005
Published: 2019
Journal Articles

Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study

Philippe Armand, MD PhD, Margaret A. Shipp, MD, Vincent Ribrag, MD, Jean-Marie Michot, MD, Pier Luigi Zinzani, MD PhD, John Kuruvilla, MD, Ying Zhu, PhD, Alejandro Daniel Ricart, MD, Arun Balakumaran, MD PhD SM, Craig H. Moskowitz, MD
Journal: Blood
Blood (2016) 128 (22): 1108.
https://doi.org/10.1182/blood.V128.22.1108.1108
Published: 2016
Journal Articles

Molecular and Genetic Characterization of Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As Initial Treatment of Chronic Lymphocytic Leukemia (CLL)

Xavier C Badoux, MB BS, Giles Best, BSc (Hons), PhD, Sara Gabrielli, Miss, Melanie Hayes, PhD, Ying Zhu, PhD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Bryone J Kuss, MBBS, PhD FRCPA, FRACP
Journal: Blood
Blood (2014) 124 (21): 1959.
https://doi.org/10.1182/blood.V124.21.1959.1959
Published: 2014
Journal Articles

Genomic Profiling In Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (ALLG CLL5 OFOCIR trial) As Initial Treatment Of Chronic Lymphocytic Leukemia (CLL)

XAVIER BADOUX, MBBS FRACP FRCPA, Giles Best, BSc (Hons) Ph.D., Sara Gabrielli, Miss, Ying Zhu, PhD, Melanie Hayes, PhD, Bryone J Kuss, MBBS, PhD, FRCPA, William Stevenson, MBBS, PhD, Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA
Journal: Blood
Blood (2013) 122 (21): 1624.
https://doi.org/10.1182/blood.V122.21.1624.1624
Published: 2013